Want to see IN:STAR full AI Analyst Report?
STAR Stock Chart & Stats
₹1019.00
₹23.00(2.25%)
At close: 4:00 PM EDT
₹1019.00
₹23.00(2.25%)
Day’s Range― - ―
52-Week Range₹769.60 - ₹1,231.45
Previous CloseN/A
Volume248.70K
Average Volume (3M)12.54K
Market Cap
₹89.23B
Enterprise Value₹102.30K
Total Cash (Recent Filing)₹2.13B
Total Debt (Recent Filing)₹17.58B
Price to Earnings (P/E)14.8
Beta0.93
Next Earnings
Nov 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.51%
Share Statistics
EPS (TTM)60.35
Shares Outstanding92,172,714
10 Day Avg. Volume13,417
30 Day Avg. Volume12,536
Financial Highlights & Ratios
PEG Ratio0.42
Price to Book (P/B)2.78
Price to Sales (P/S)1.78
P/FCF Ratio71.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)68
Revenue Forecast (FY)₹58.08B
Bulls Say, Bears Say
Bulls Say
Profitability TurnaroundStrides moved from losses to solid profits in 2025–2026 with gross margin ~36% and net margin ~11%. This improvement signals structurally stronger product mix and pricing, supporting sustainable earnings power, reinvestment in regulatory filings, and a more durable ability to cover operating costs over months.
Improved Leverage And ReturnsDebt-to-equity falling to ~0.57x and ROE rebounding to ~18% indicate materially improved capital structure and profitability versus recent years. Improved leverage reduces interest burden and increases financial flexibility for manufacturing investments, filings, or selective M&A over the medium term.
Diversified Generics And CDMO ModelStrides operates across finished generics, specialty pharmaceuticals, and contract development/manufacturing supplying regulated and emerging markets. This mix diversifies revenue sources, spreads regulatory and tender risk across geographies and partners, and supports repeatable manufacturing cashflows over time.
Bears Say
Weak Free Cash Flow ConversionFCF weakness — a ~50% YoY decline and FCF only ~22% of net income — shows earnings are not fully converting to cash. That limits internal funding for capex, registrations, debt reduction or dividends and raises reliance on external financing if cash conversion does not stabilize.
Prior Earnings VolatilityHistorical losses and margin swings through 2022–2024 reflect execution and cycle risk common in generics and tender-driven markets. The pattern implies profits can revert under pricing pressure, regulatory delays or competitive entries, creating recurring operational risk over the medium term.
Meaningful Absolute Debt LevelAlthough leverage improved, absolute debt is still material and resilience is not yet best-in-class. Given the recent recovery from stressed profitability, lingering debt levels could constrain strategic flexibility and increase vulnerability if cash generation weakens or industry conditions worsen.
Strides Pharma Science Ltd News
STAR FAQ
What was Strides Pharma Science Ltd’s price range in the past 12 months?
Strides Pharma Science Ltd lowest stock price was ₹769.60 and its highest was ₹1231.45 in the past 12 months.
What is Strides Pharma Science Ltd’s market cap?
Strides Pharma Science Ltd’s market cap is ₹89.23B.
When is Strides Pharma Science Ltd’s upcoming earnings report date?
Strides Pharma Science Ltd’s upcoming earnings report date is Nov 04, 2026 which is in 78 days.
How were Strides Pharma Science Ltd’s earnings last quarter?
Strides Pharma Science Ltd released its earnings results on Jul 31, 2026. The company reported ₹17 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Strides Pharma Science Ltd overvalued?
According to Wall Street analysts Strides Pharma Science Ltd’s price is currently Overvalued.
Does Strides Pharma Science Ltd pay dividends?
Strides Pharma Science Ltd pays a Annually dividend of ₹5 which represents an annual dividend yield of 0.51%. See more information on Strides Pharma Science Ltd dividends here
What is Strides Pharma Science Ltd’s EPS estimate?
Strides Pharma Science Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Strides Pharma Science Ltd have?
Strides Pharma Science Ltd has 92,172,714 shares outstanding.
What happened to Strides Pharma Science Ltd’s price movement after its last earnings report?
Strides Pharma Science Ltd reported an EPS of ₹17 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.226%.
Which hedge fund is a major shareholder of Strides Pharma Science Ltd?
Currently, no hedge funds are holding shares in IN:STAR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Strides Pharma Science Ltd
Strides Pharma Science Limited is a pharmaceutical company that focuses on the development, production, and worldwide commercialization of medicinal products. Its extensive global footprint spans Africa, Australia, North America, Europe, Asia, India, and various other international markets. The company's operations are structured into two distinct segments: Pharmaceutical and Biopharmaceutical. It provides a diverse range of generic pharmaceuticals, available in multiple formats including tablets, hard and soft gelatin capsules, sachets, liquids, nasal sprays, powders, solids, ointments, and creams. Furthermore, Strides Pharma Science creates branded generic offerings for treating chronic ailments such as women's health issues, central nervous system disorders, cardiovascular conditions, diabetes, dermatological concerns, and probiotic support, marketed under brands like Renerve, Unibrol, Combiart, Duotab, and Vitafer. For institutional business, the company supplies drugs targeting infectious diseases, including anti-retrovirals, anti-malarials, anti-tuberculosis, and Hepatitis treatments. Incorporated in 1990, the company is headquartered in Bengaluru, India. It was formerly known as Strides Shasun Limited before adopting its current name in July 2018.
Technical Analysis
Aurobindo Pharma Ltd
―
Dr. Reddy's Laboratories Ltd.
―
Laurus Labs Ltd.
―
Piramal Pharma Limited
―
Sun Pharmaceutical Industries Limited
―